5 Citations (Scopus)


α-Synuclein (a-syn) oligomers and fibrils are behind neurodegeneration in Parkinson's disease (PD), but therapeutically targeting them is challenging. Amphipathic and cationic helical peptides inhibit amyloid formation and suppress neurotoxicity by selectively binding the solvent-accessible regions in these toxic species. Can endogenous peptides, like LL-37, constitute a new therapeutic paradigm in PD?

Original languageEnglish
Pages (from-to)641-644
Number of pages4
JournalTrends in Biochemical Sciences
Issue number8
Early online date19 Feb 2022
Publication statusPublished - 1 Aug 2022


  • amyloid fibril
  • disease-modifying therapy
  • LL-37
  • oligomer
  • Parkinson's disease
  • α-synuclein


Dive into the research topics of 'Is a cure for Parkinson's disease hiding inside us?'. Together they form a unique fingerprint.

Cite this